FDA Rebuttals & Adwork (45-fda-rebuttles-and-adwork)
Inventory item: 8495 | SKU: 2076 | Line: Blueprints
Page: https://cri-one.com/45-fda-rebuttles-and-adwork.html
Owner and author: Christopher Gabriel Brown (CRI-ONE)
Record date: 8 October 2026
Approved public wording item: medical and regulatory wording follows the approved public description (descriptions-public).
1. The Record in Brief
FDA Rebuttals & Adwork is a regulatory-positioning and marketing package that assembles six health-science sub-projects - disease-mechanism research dossiers for diabetes, Alzheimer's and Parkinson's, a 300-disease mechanism-research database, the NeuroElement brain-chemistry system and the Health Recovery portfolio - with FDA/FTC positioning memos, red-team and steelman proofs, a compliance checklist and automated validation tooling (D:/special/_inventory/descriptions-public/8495.md). Its earliest dated disclosures are Christopher Gabriel Brown's depositions 133, 148, 201 and 373, each carried in the 2017 buyinvent.com catalog under the mark "copyright © 2017 chris g brown" (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). Two pending USPTO applications are mapped to this product directly - U.S. Application No. 19/441,975 (filed 7 January 2026) and U.S. Application No. 19/445,644 (filed 12 January 2026) - and four more pending applications cover its bundled sub-projects (D:/Rebuttals/_registers/USPTO_REGISTER.json). The product was first listed as blueprint record SKU 2076 on the cri-one.com store on 31 August 2026 and is offered today on its own item page with a live card Buy button from 05:06 UTC on 8 October 2026. Copyright in every text, drawing, line of code and data compilation in the package belongs to its author from fixation, and the package carries the written notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved."
2. Proprietary - What Is Owned and How It Is Held
The package is a single folder of 812 files: six sub-project directories (Projects 10, 11, 12, 13, 22 and 33), three root tooling files (FDA_COMPLIANCE_CHECKLIST.md, validate_rebuttals.py, make_product_zips.py), a _product_zips directory of six pre-built archives, and the package index _TOC.md with its _TOC.html copy (generated 2026-10-06; it counts 810 content files). The file families on disk are:
| Family | Count | Examples |
|---|---|---|
| Documentation (.md) | 471 | 6 FDA_REBUTTAL memos, 6 red-team and 6 steelman proofs |
| Source code (.py) | 103 | validate_rebuttals.py, discovery runners, NeuroElement CLI |
| Vector drawings (.svg) | 46 | 25 patent figure drawings, 12 sheets at 11x17 |
| Data (.json) | 37 | discovery findings, brain-chemistry databases |
| Web pages (.html) | 37 | START_HERE, WEB_DESCRIPTION, store descriptions |
| Text, PDF, archives | 30 / 15 / 12 | paste-ready claims, USPTO receipts, product ZIPs |
The package also carries patent-application drafts and paste-ready filing texts for the diabetes, Alzheimer's, Parkinson's, NeuroElement and Health Recovery subject matter, 6 essays, 6 rebuttal-note files, 4 safety disclaimers, 4 methodology disclosures and 6 CITATION.cff records (counts taken from the folder).
Ownership is sole. Every sub-project LICENSE names Christopher Gabriel Brown as exclusive owner, every patent document names him as sole inventor (D:/special/_inventory/descriptions-public/8495.md), and no assignment is of record. The owner's own license text (Evidence 3) states: "NO LICENSE IS GRANTED. No part of this Work may be copied, modified, distributed, sublicensed, sold, published, or otherwise transferred without the express written permission of the copyright holder." A buyer receives use only: the purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." Every Payment Link carries it as a required "Purchase term" the buyer must agree to at checkout (D:/special/crione-static/build_terms.py), and the item page repeats it beside the Buy button (D:/special/crione-static/site-inventory/inventory/item-8495/index.html).
The package is held under reasonable secrecy measures within 18 U.S.C. 1839(3). The full package is delivered only to paying buyers, by private time-limited download link sent by e-mail after payment (D:/special/crione-static/delivery-v2/deliver.py); the delivery file of record is 45-fda-rebuttles-and-adwork__2026-09-04.zip, 40,975,163 bytes (D:/special/crione-static/delivery-v2/product_deliverables.csv). The mutual NDA is published at https://cri-one.com/nda/ and its full text travels with every delivery e-mail. The public item page carries only the description.
3. First Art - The Earliest Dated Disclosure
| Date | Record | What it discloses | Source |
|---|---|---|---|
| 2017 | Deposition 133, 2017 catalog | Receptor-site measurement of dopamine, serotonin, adrenaline and histamine | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv |
| 2017 | Deposition 148, 2017 catalog | Healthy-baseline chemistry and organ pH balance method | same; IP register line 535 |
| 2017 | Deposition 201, 2017 catalog | Immune-pathway insulin concept | same; IP register line 871 |
| 2017 | Deposition 373, 2017 catalog | Toxicity and valence testing across diseases including Alzheimer's | same; IP register line 1061 |
| 2017-11-24 | Invent Depositions, ISBN 978-1-979767-89-7 | Printed 2017 collection of Christopher Gabriel Brown's depositions | D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md |
| 2026-01-07 | U.S. Application No. 19/441,975 | Zinc-amino acid complexes, Alzheimer's subject | D:/USPTO Responses/Receipts/N417diabetes.pdf |
| 2026-01-12 | U.S. Application No. 19/445,644 | Metal-amino acid complexes, Parkinson's subject | D:/USPTO Responses/Receipts/N417parkinsons.pdf |
Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_B.json, confirmed against the master IP register D:/special/82-alchemy-calc-two/1 light trigger.txt):
- Deposition 373 (IP register line 1061; anchor: 2017 catalog): "toxic and valance testing to include but not limited to cancer and diseases like alzheimer's and substance abuse cessation aids." It is the screening method behind the Alzheimer's research dossier.
- Deposition 201 (line 871; anchor: 2017 catalog): "immune systemic insulin. insulin medicine to magistrate through the auto immune system". It seeds the diabetes research dossier.
- Deposition 148 (line 535; anchor: 2017 catalog): "can we figure out the chemistry in a healthy human, then make a ph balance inside each organ including the brain and thus making chemistry balance". It is the basis of the 300-disease research database.
- Deposition 133 (line 369; anchor: 2017 catalog): "mission 1 diagnose changes at dopa mine serotonin adrenaline and histamine receptor sites in the central nervous system by using a similar method to diabetic blood testing." It is the brain-chemistry basis of NeuroElement.
Each of the four catalog entries carries the mark "copyright © 2017 chris g brown" and a buyinvent.com product image URL bearing its deposition number (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). The origin-story records for all four are on file in D:/manager/book-ocr-2017-invent-depositions/origin-stories/.
Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 depositions are dated public disclosures in the owner's name, so they stand against every later filer on the same subject matter. A challenger must produce a dated record earlier than these 2017 entries disclosing the same combination. None is of record.
Prior Art Considered and Distinguished
The site provenance record for SKU 2076 lists six portfolio-level references, all from the owner's own LED photon-recycling and portfolio prior-art tables (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json; titles as recorded in D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json). No product-specific search file exists in this package; its google_patents_search_list.txt indexes the owner's own application numbers, not third-party art.
| Reference | Title as recorded | Distinction |
|---|---|---|
| US 4,775,876 | Photon recycling light emitting diode | LED photon recycling; discloses no disease-mechanism dossier or regulatory memo |
| US 2010/0183919 A1 | Quantum dot ultracapacitor and electron battery | Energy storage; no health-research content |
| US 2012/0305059 A1 | Photon recycling in an optoelectronic device | Optoelectronics; no health-research content |
| US 6,175,719 B1 | Multi-Spot-Beam Satellite | Satellite payload; outside this subject matter |
| US 7,418,236 B2 | Extraterrestrial Communications Systems | Satellite-terrestrial communications; outside this subject matter |
| US 11,258,379 B2 | Quantum Noise Power Devices | Energy harvesting; outside this subject matter |
4. First to File - The USPTO Record
| U.S. Application | Filed | Status of record | What it covers for this product | Source |
|---|---|---|---|---|
| 19/441,975 | 2026-01-07 | Pending (Conf. [redacted]); reply recorded filed 2026-09-17 | Alzheimer's research dossier (Project 11) | USPTO_REGISTER.json; Evidence 4 |
| 19/445,644 | 2026-01-12 | Pending (Conf. [redacted]); reply recorded filed 2026-09-17 | Parkinson's research dossier (Project 12) | USPTO_REGISTER.json; Evidence 5 |
| 19/555,525 | 2026-03-03 | Pending (Conf. [redacted]); Filing Receipt 2026-08-13 | Bundled NeuroElement sub-project (Project 22) | USPTO_REGISTER.json; Evidence 6 |
| 19/630,444 | 2026-03-27 | Pending (Conf. [redacted]) | Bundled Health Recovery sub-project (Project 33) | USPTO_REGISTER.json; Evidence 7 |
| 19/540,453 | 2026-02-13 | Pending (Conf. [redacted]); Filing Receipt 2026-07-27 | Umbrella filing naming the disease discovery systems (Projects 10-13) | USPTO_REGISTER.json |
| 19/747,949 | 2026-07-20 | Pending (Conf. [redacted]) | Diabetes and 300-disease subject matter (Projects 10, 13) | USPTO_REGISTER.json |
The register maps 19/441,975 and 19/445,644 to this product directly; the other four are mapped by the register to the sub-projects this package bundles. The USPTO acknowledgement receipt for 19/445,644 is kept inside the package itself, byte-identical to the receipt of record (SHA-256 bb5b87bad4927f62), as are the receipts for 19/555,525 (ca48a9d5f3d7e7f8) and 19/630,444 (2c8eededd0c15fa1). Each application is dated by its own effective filing date under the first-inventor-to-file system in force since 16 March 2013; none carries a benefit claim of record. Marking is correct under 35 U.S.C. 292 while these applications are pending, and the package LICENSE already carries the patent-pending notice for 19/441,975 (Evidence 3).
Marking line: Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.
5. First to Market - The Dated Public Offering
| Date | Event | Where | Source |
|---|---|---|---|
| 2014-03-05 | First Internet Archive capture of buyinvent.com, the 2017 catalog venue | web.archive.org | D:/manager/first-to-market/wayback_evidence.json |
| 2017 | Depositions 133, 148, 201, 373 listed with copyright marks | buyinvent.com product line | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv |
| 2017-11-24 | Invent Depositions first shipped | CreateSpace / print | D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md |
| 2026-08-31 | Blueprint record SKU 2076 created in Enterprise blueprints | old cri-one.com store | D:/manager/_store/export_catalog_product_20260831_201548.csv |
| 2026-09-01 | Record re-created; kept in the 2026-09-07 catalog export | old cri-one.com store | D:/manager/export_catalog_product_20260907_110415.csv |
| 2026-09-04 | Delivery file of record date-marked | private delivery copies | D:/special/crione-static/delivery-v2/product_deliverables.csv |
| 2026-10-08 | Item page published | https://cri-one.com/45-fda-rebuttles-and-adwork.html | D:/special/crione-static/site-inventory/inventory/item-8495/index.html |
| 2026-10-08 05:06 UTC | Stripe card Payment Link (created 04:56:14Z) public as the Buy button | item page | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json |
The first new-site email campaign to US company prospects started at 03:55 UTC on 8 October 2026 from christopher@cri-one.com (D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json).
6. Copyright
© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved.
The works covered are the expression in this package: the memo, essay, proof, checklist and description text; the 46 vector drawings, including 25 patent figure drawings and 12 reference, formulation and recipe sheets at 11x17; the 103 Python source files, including validate_rebuttals.py; the 37 JSON data compilations; the 37 web pages; and the 2017 deposition text from which the dossiers grew. Copyright arose on fixation of each work (17 U.S.C. 102(a)). It protects this expression, not the methods or compositions the works describe (17 U.S.C. 102(b)); method and composition are held by the pending applications in Section 4 and by confidentiality.
The corpus is anchored by the owner's verified Copyright Office registrations, among them TX 8-432-699 (cabbagestalk 11, effective 2017-01-13), TX 8-396-625 (abstract, 2017-05-09), TX 8-648-723 (2018, 2018-09-10), TX 8-657-127 (buy text, 2018-10-04) and TX 9-504-677 (estimated, 2025-05-06) - 19 verified certificates in all, effective 2010-10-01 to 2025-05-06 (D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json). Registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).
Human authorship: protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the concept, the numbered depositions written by Christopher Gabriel Brown, and his selection, arrangement and direction of the six sub-projects, the memos and the collateral into one package.
Notice practice: the 2017 catalog entries carry "copyright © 2017 chris g brown"; each of the six sub-project LICENSE files carries "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." The notice defeats an innocent-infringer defense (17 U.S.C. 401(d)).
7. Firm Rebuttals
Challenge 1 - "This is not original; disease-chemistry research is old art."
Rebuttal. The record is dated. Depositions 133, 148, 201 and 373 were published in the owner's name in the 2017 catalog, each under a 2017 copyright mark (D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv). The only references considered for SKU 2076 address LED photon recycling, energy storage, satellites and energy harvesting (Section 3); none discloses a disease-mechanism research dossier combined with FDA/FTC positioning memos, adversarial proofs and automated validation tooling. A challenger must produce a dated record earlier than 2017 disclosing the same combination. None is of record.
Challenge 2 - "Someone filed first."
Rebuttal. Six applications in the owner's name are of record from 7 January 2026 forward, each dated by its own USPTO receipt (Section 4). The 2017 depositions are prior art under 35 U.S.C. 102(a)(1) against any later filer on the same subject matter. A challenger must produce an effective filing date, or a public disclosure, earlier than the owner's dated records on the same combination. None is of record.
Challenge 3 - "No patent has issued, so there is nothing to respect."
Rebuttal. The owner holds pending applications 19/441,975 and 19/445,644, and "patent pending" marking is correct while they are pending (35 U.S.C. 292). Protection does not wait on examination: the package is held as a trade secret under 18 U.S.C. 1839(3), delivered only under the purchase term and NDA, and its expression is protected by copyright from fixation.
Challenge 4 - "The depositions were published, so the package is free to use."
Rebuttal. Publication of a one-line deposition in 2017 made it prior art against later filers; it did not publish the package. The 812-file package - memos, proofs, code, data and drawings - is delivered only to paying buyers by private link, and the buyer receives "the use of that blueprint only" (https://cri-one.com/terms). The LICENSE grants no license to copy, distribute or publish (Evidence 3).
Challenge 5 - "AI made it, so there is no copyright."
Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown, the concept, and his selection, coordination and arrangement of six sub-projects and their regulatory overlay into one work. That is the expression the U.S. Copyright Office guidance of March 2023 protects. The owner's registration practice at the Copyright Office runs from 2010 through 2025 across 19 verified certificates.
Challenge 6 - "The dates can be faked."
Rebuttal. The dates rest on third-party records. Invent Depositions carries ISBN 978-1-979767-89-7, and its CreateSpace label records first shipment on 2017-11-24. The Internet Archive's own first capture of buyinvent.com is 2014-03-05 (D:/manager/first-to-market/wayback_evidence.json). The USPTO's electronic acknowledgement receipts fix 7 January 2026 (19/441,975, Patent Center 73872206) and 12 January 2026, 1:28:59 AM ET (19/445,644, Patent Center 73928275). Every evidence file is fingerprinted by SHA-256 in Section 8 and in D:/Rebuttals/_evidence/8495.sha256.
Challenge 7 - "This is an unlawful disease claim."
Rebuttal. The package is research and discovery IP. It makes no treatment claim, sells no consumable and pairs no consumable with its information. Its own memos establish that every biological statement is attributed to cited third-party literature and that the research is licensed business-to-business under NDA (D:/special/_inventory/descriptions-public/8495.md). The package executes that position with a seven-part compliance checklist, four safety disclaimers, four methodology disclosures and an automated checker that scans for forbidden strings, disclaimer presence and therapeutic-claim leaks (D:/special/45-fda-rebuttles-and-adwork/validate_rebuttals.py). The public item page uses the approved public wording.
Challenge 8 - "It is just an idea."
Rebuttal. The package is concrete work product: 103 Python source files, 37 JSON data compilations, 46 vector drawings including 25 patent figure drawings, application drafts and paste-ready filing texts for five subject areas, 6 objection-by-objection FDA/FTC memos, 6 red-team and 6 steelman proofs, and six pre-built product archives (Section 2). Three USPTO acknowledgement receipts sit inside it, byte-identical by SHA-256 to the receipts of record.
8. Evidence Index
| # | File | SHA-256 (first 16 hex) | What it proves |
|---|---|---|---|
| 1 | D:/special/_inventory/descriptions-public/8495.md | 82b330d2a2ef710c | Approved public description; package contents and regulatory thesis |
| 2 | D:/special/45-fda-rebuttles-and-adwork/_TOC.md | cf7c9dd48706f79e | Package index of 2026-10-06; file listing |
| 3 | D:/special/45-fda-rebuttles-and-adwork/11-alzheimers-cure-discovery/LICENSE | e19b40f334497eb2 | Copyright notice, exclusive ownership, no-license grant, patent-pending notice |
| 4 | D:/USPTO Responses/Receipts/N417diabetes.pdf | a2aa6ac673f1873f | USPTO receipt, 19/441,975, 2026-01-07 |
| 5 | D:/USPTO Responses/Receipts/N417parkinsons.pdf | bb5b87bad4927f62 | USPTO receipt, 19/445,644, 2026-01-12; identical copy in package |
| 6 | D:/USPTO Responses/Receipts/N417 (14).pdf | ca48a9d5f3d7e7f8 | USPTO receipt, 19/555,525; identical copy in package |
| 7 | D:/USPTO Responses/Receipts/N417 (10).pdf | 2c8eededd0c15fa1 | USPTO receipt, 19/630,444; identical copy in package |
| 8 | D:/Rebuttals/_registers/USPTO_REGISTER.json | ded33340c9582bd9 | Filing dates, statuses and product mapping |
| 9 | D:/special/82-alchemy-calc-two/1 light trigger.txt | 2dcb359de3f1b56d | Master IP register; depositions 133, 148, 201, 373 |
| 10 | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv | ad3b87e885814dbb | 2017 catalog entries with 2017 copyright marks |
| 11 | D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json | 4245280e5b3aea54 | Prior art considered for SKU 2076 |
| 12 | D:/manager/first-to-market/wayback_evidence.json | a0dde412013594b5 | Internet Archive first captures |
| 13 | D:/manager/export_catalog_product_20260907_110415.csv | 12be9abf793c5f86 | Old-store blueprint record SKU 2076 |
| 14 | D:/special/crione-static/site-inventory/inventory/item-8495/index.html | d05aaf3a3bf10e3d | Item page, purchase term, public wording |
| 15 | D:/special/crione-static/delivery-v2/payment_links_ledger.live.json | 96abb64653254b86 | Card Payment Link created 2026-10-08T04:56:14Z |
| 16 | D:/special/crione-static/delivery-v2/deliver.py | a4ace02b3b7d341b | Paid-only delivery by time-limited private link; NDA text with every delivery e-mail |
| 17 | D:/special/crione-static/build_terms.py | 52a11d133023119d | Purchase term required at checkout on every Payment Link |
9. Notice Line
© 2017-2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/441,975 and 19/445,644.
cri-one.com/45-fda-rebuttles-and-adwork.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.Go to cart